Biologics in the management of ulcerative colitis – comparative safety and efficacy of TNF-α antagonists

References

• OstermanMTLichtensteinGRUlcerative ColitisSleisengerMHFeldmanMFriedmanLSBrandtLJSleisenger and Fordtran’s gastrointestinal and liver disease pathophysiology, diagnosis, management9th edPhiladelphia, PASaunders/Elsevier201019752013
   Google Scholar
• McIntyrePBPembertonJHWolffBGBeartRWDozoisRRComparing functional results one year and ten years after ileal pouch-anal anastomosis for chronic ulcerative colitisDis Colon Rectum19943743033078168407
   PubMed Web of Science ®Google Scholar
• LangholzEMunkholmPDavidsenMBinderVColorectal cancer risk and mortality in patients with ulcerative colitisGastroenterology19921035144414511358741
   PubMed Web of Science ®Google Scholar
• TargownikLESinghHNugentZBernsteinCNThe epidemiology of colectomy in ulcerative colitis: results from a population-based cohortAm J Gastroenterol201210781228123522613902
   PubMed Web of Science ®Google Scholar
• PennaCDozoisRTremaineWPouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitisGut19963822342398801203
   PubMed Web of Science ®Google Scholar
• BillietTRutgeertsPFerranteMVan AsscheGVermeireSTargeting TNF-alpha for the treatment of inflammatory bowel diseaseExpert Opin Biol Ther20141417510124206084
   PubMed Web of Science ®Google Scholar
• MurchSHLamkinVASavageMOWalker-SmithJAMacDonaldTTSerum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel diseaseGut19913289139171885073
   PubMed Web of Science ®Google Scholar
• MurchSHBraeggerCPWalker-SmithJAMacDonaldTTLocation of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel diseaseGut19933412170517098031350
   PubMed Web of Science ®Google Scholar
• BraeggerCPNichollsSMurchSHStephensSMacDonaldTTTumour necrosis factor alpha in stool as a marker of intestinal inflammationLancet1992339878589911345871
   PubMed Web of Science ®Google Scholar
• ScallonBJMooreMATrinhHKnightDMGhrayebJChimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functionsCytokine1995732512597640345
   PubMed Web of Science ®Google Scholar
• TraceyDKlareskogLSassoEHSalfeldJGTakPPTumor necrosis factor antagonist mechanisms of action: a comprehensive reviewPharmacol Ther2008117224427918155297
   PubMed Web of Science ®Google Scholar
• HanauerSBFeaganBGLichtensteinGRMaintenance infliximab for Crohn’s disease: the ACCENT I randomised trialLancet200235993171541154912047962
   PubMed Web of Science ®Google Scholar
• SandsBEAndersonFHBernsteinCNInfliximab maintenance therapy for fistulizing Crohn’s diseaseN Engl J Med2004350987688514985485
   PubMed Web of Science ®Google Scholar
• CheyWYInfliximab for patients with refractory ulcerative colitisInflamm Bowel Dis20017Suppl 1S30S3311380041
   PubMedGoogle Scholar
• SandsBETremaineWJSandbornWJInfliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot studyInflamm Bowel Dis200172838811383595
   PubMed Web of Science ®Google Scholar
• SuCSalzbergBALewisJDEfficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitisAm J Gastroenterol200297102577258412385442
   PubMed Web of Science ®Google Scholar
• RutgeertsPSandbornWJFeaganBGInfliximab for induction and maintenance therapy for ulcerative colitisN Engl J Med2005353232462247616339095
   PubMed Web of Science ®Google Scholar
• FeaganBGReinischWRutgeertsPThe effects of infliximab therapy on health-related quality of life in ulcerative colitis patientsAm J Gastroenterol2007102479480217324131
   PubMed Web of Science ®Google Scholar
• SandbornWJRutgeertsPFeaganBGColectomy rate comparison after treatment of ulcerative colitis with placebo or infliximabGastroenterology200913741250126019596014
   PubMed Web of Science ®Google Scholar
• KopylovUMantzarisGJKatsanosKHThe efficacy of shortening the dosing interval to once every six weeks in Crohn’s patients losing response to maintenance dose of infliximabAliment Pharmacol Ther201133334935721118397
   PubMed Web of Science ®Google Scholar
• SeowCHNewmanAIrwinSPSteinhartAHSilverbergMSGreenbergGRTrough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitisGut2010591495419651627
   PubMed Web of Science ®Google Scholar
• TaxoneraCOlivaresDMendozaJLDíaz-RubioMReyENeed for infliximab dose intensification in Crohn’s disease and ulcerative colitisWorld J Gastroenterol201420279170917725083091
   PubMed Web of Science ®Google Scholar
• RostholderEAhmedACheifetzASMossACOutcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitisAliment Pharmacol Ther201235556256722239070
   PubMed Web of Science ®Google Scholar
• YamadaSYoshinoTMatsuuraMLong-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experienceBMC Gastroenterol2014148024758588
   PubMed Web of Science ®Google Scholar
• CesariniMKatsanosKPapamichaelKDose optimization is effective in ulcerative colitis patients losing response to infliximab: a collaborative multicentre retrospective studyDig Liver Dis201446213513924246151
   PubMedGoogle Scholar
• JarnerotGHertervigEFriis-LibyIInfliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled studyGastroenterology200512871805181115940615
   PubMed Web of Science ®Google Scholar
• NavesJELlaoJRuiz-CerullaALong-term Comparative Efficacy of Cyclosporine- or Infliximab-based Strategies for the Management of Steroid-refractory Ulcerative Colitis AttacksInflamm Bowel Dis20142081375138125046008
   PubMed Web of Science ®Google Scholar
• CroftAWalshADoeckeJCooleyRHowlettMRadford-SmithGOutcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs infliximabAliment Pharmacol Ther201338329430223786158
   PubMed Web of Science ®Google Scholar
• LaharieDBourreilleABrancheJCiclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trialLancet201238098571909191523063316
   PubMed Web of Science ®Google Scholar
• GibsonDJHeetunZSRedmondCEAn Accelerated Infliximab Induction Regimen Reduces the Need for Early Colectomy in Patients with Acute Severe Ulcerative ColitisClin Gastroenterol Hepatol Epub2014730
   Web of Science ®Google Scholar
• AfifWLeightonJAHanauerSBOpen-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximabInflamm Bowel Dis20091591302130719408340
   PubMed Web of Science ®Google Scholar
• Peyrin-BirouletLLaclotteCRoblinXBigardMAAdalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label studyWorld J Gastroenterol200713162328233217511032
   PubMed Web of Science ®Google Scholar
• ReinischWSandbornWJHommesDWAdalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trialGut201160678078721209123
   PubMed Web of Science ®Google Scholar
• SandbornWJvan AsscheGReinischWAdalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitisGastroenterology2012142225726522062358
   PubMed Web of Science ®Google Scholar
• TaxoneraCEstellesJFernandez-BlancoIAdalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximabAliment Pharmacol Ther201133334034821133961
   PubMed Web of Science ®Google Scholar
• FeaganBGSandbornWJLazarAAdalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitisGastroenterology2014146111011824067881
   PubMed Web of Science ®Google Scholar
• WolfDD’HaensGSandbornWJEscalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitisAliment Pharmacol Ther201440548649725041859
   PubMed Web of Science ®Google Scholar
• ShealyDJCaiAStaquetKCharacterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alphaMAbs20102442843920519961
   PubMed Web of Science ®Google Scholar
• SandbornWJFeaganBGMaranoCSubcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitisGastroenterology20141461859523735746
   PubMed Web of Science ®Google Scholar
• SandbornWJFeaganBGMaranoCSubcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitisGastroenterology201414619610923770005
   PubMed Web of Science ®Google Scholar
• HanauerSBStill in pursuitGastroenterology20141461131524287301
   PubMed Web of Science ®Google Scholar
• PanaccioneRGhoshSMiddletonSCombination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitisGastroenterology2014146239240024512909
   PubMed Web of Science ®Google Scholar
• ColombelJFSandbornWJReinischWInfliximab, azathioprine, or combination therapy for Crohn’s diseaseN Engl J Med2010362151383139520393175
   PubMed Web of Science ®Google Scholar
• KamathNKamathAPaiCGInfliximab for Moderate to Severe Ulcerative Colitis: The Jury Isn’t in YetGastroenterology2014147254454524973682
   PubMed Web of Science ®Google Scholar
• NielsenOHAinsworthMATumor necrosis factor inhibitors for inflammatory bowel diseaseN Engl J Med2013369875476223964937
   PubMed Web of Science ®Google Scholar
• SandsBESiegelCACrohn’s DiseaseSleisengerMHFeldmanMFriedmanLSBrandtLJSleisenger and Fordtran’s gastrointestinal and liver disease pathophysiology, diagnosis, management9th edPhiladelphia, PASaunders/Elsevier201019411973
   Google Scholar
• VermeireSNomanMVan AsscheGAutoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn’s disease: a prospective cohort studyGastroenterology20031251323912851868
   PubMed Web of Science ®Google Scholar
• CullenGKroshinskyDCheifetzASKorzenikJRPsoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literatureAliment Pharmacol Ther20113411–121318132721957906
   PubMed Web of Science ®Google Scholar
• LichtensteinGRFeaganBGCohenRDSerious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT registryAm J Gastroenterol201210791409142222890223
   PubMed Web of Science ®Google Scholar
• MarehbianJArrighiHMHassSTianHSandbornWJAdverse events associated with common therapy regimens for moderate-to-severe Crohn’s diseaseAm J Gastroenterol2009104102524253319532125
   PubMed Web of Science ®Google Scholar
• TargownikLEBernsteinCNInfectious and malignant complications of TNF inhibitor therapy in IBDAm J Gastroenterol2013108121835184224042192
   PubMed Web of Science ®Google Scholar
• SinghJAWellsGAChristensenRAdverse effects of biologics: a network meta-analysis and Cochrane overviewCochrane Database Syst Rev20112CD00879421328309
   PubMed Web of Science ®Google Scholar
• Peyrin-BirouletLDeltenrePde SurayNBrancheJSandbornWJColombelJFEfficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trialsClin Gastroenterol Hepatol20086664465318550004
   PubMed Web of Science ®Google Scholar
• MichaudTLRhoYHShamliyanTKuntzKMChoiHKThe Comparative Safety of TNF Inhibitors in Rheumatoid Arthritis – A Meta-Analysis Update of 44 Randomized Controlled TrialsAm J Med Epub2014617
   PubMed Web of Science ®Google Scholar
• KavanaughAMcInnesIBMeasePClinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study)Ann Rheum Dis20147391689169424748630
   PubMed Web of Science ®Google Scholar
• OstermanMTSandbornWJColombelJFIncreased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn’s diseaseGastroenterology2014146494194924361468
   PubMed Web of Science ®Google Scholar
• SiegelCAMardenSMPersingSMLarsonRJSandsBERisk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysisClin Gastroenterol Hepatol20097887488119558997
   PubMed Web of Science ®Google Scholar
• CaspersenSElkjaerMRiisLInfliximab for inflammatory bowel disease in Denmark 1999–2005: clinical outcome and follow-up evaluation of malignancy and mortalityClin Gastroenterol Hepatol20086111212121718848503
   PubMed Web of Science ®Google Scholar
• LongMDHerfarthHHPipkinCAPorterCQSandlerRSKappelmanMDIncreased risk for non-melanoma skin cancer in patients with inflammatory bowel diseaseClin Gastroenterol Hepatol20108326827420005977
   PubMed Web of Science ®Google Scholar
• LongMDMartinCFPipkinCAHerfarthHHSandlerRSKappelmanMDRisk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel diseaseGastroenterology2012143239039922584081
   PubMed Web of Science ®Google Scholar
• ThorlundKDruytsEMillsEJFedorakRNMarshallJKAdalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naive to anti-TNF therapy: an indirect treatment comparison meta-analysisJ Crohns Colitis20148757158124491514
   PubMed Web of Science ®Google Scholar
• DaneseSFiorinoGPeyrin-BirouletLBiological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysisAnn Intern Med20141601070471124842416
   PubMed Web of Science ®Google Scholar
• ProbertCSHearingSDSchreiberSInfliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trialGut2003527998100212801957
   PubMed Web of Science ®Google Scholar
• StidhamRWLeeTCHigginsPDSystematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitisAliment Pharmacol Ther201439766067124506179
   PubMed Web of Science ®Google Scholar
• FeaganBGRutgeertsPSandsBEVedolizumab as induction and maintenance therapy for ulcerative colitisN Engl J Med2013369869971023964932
   PubMed Web of Science ®Google Scholar